Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards

Anabolic Steroid Derivatives Lead to Dietary Supplement Recall

By FDA MedWatch | July 13, 2017

Sten Z and M1 Alpha capsules by Andropharm: Recall—contains derivatives of anabolic steroids.

ISSUE: 

Andropharm is voluntarily recalling all lots of Sten Z and M1 Alpha capsules to the consumer level because these products contain derivatives of anabolic steroids rendering them unapproved drugs for which safety and efficacy have not been established and therefore subject to recall.

Consumption of these products may cause elevated blood pressure, aggressive behavior, male infertility, or enlarged breasts and shrinkage of the testes in men. Patients with underlying cardiac, hepatic, or prostate conditions may be at higher risk for adverse reactions than otherwise healthy users. To date, Andropharm has not received any reports of these or any illnesses or injuries related to Sten Z or M1 Alpha.

BACKGROUND: 

Sten Z and M1 Alpha capsules are marketed as dietary supplements and promoted to increase, sustain, and strengthen muscularity. The two products were packaged as capsules in 60 count bottles with the UPC code-642125502948(Sten Z) and UPC code-642125502924(M1 Alpha) and were sold through retailers nationwide in the United States from March 2016 to April 2017. This recall applies to all lot numbers and expiration dates of these products.

RECOMMENDATION: 

Consumers who have purchased Sten Z and M1 Alpha products should discontinue their use and either return them to their place of purchase or discard the products in accordance with state and local ordinances for disposal of the drug products.

Healthcare professionals and patients are encouraged to report adverse events or side effects related to the use of these products to the FDA’s MedWatch Safety Information and Adverse Event Reporting Program: Complete and submit the report at www.fda.gov/MedWatch/report.

Click here to read MedWatch safety alerts, along with a link to the current press release.

Follow us on Twitter and Facebook for updates on the latest pharmaceutical and biopharmaceutical manufacturing news!

(Source: FDA MedWatch)

Related Articles Read More >

Fresenius Kabi
Fresenius Kabi plans to add 2D barcodes to its pharmaceutical portfolio
analyzing medical sample
Expert answers to nitrosamine impurity questions
FDA logo
FDA warns four companies over selling honey tainted with prescription drugs
FDA logo
FDA prevented 317 drug shortages in 2021

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Pharmaceutical Processing World
  • Subscribe to Our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards